GM-CSF targeting in COVID-19, an approach based on fragile foundations.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Trials of anti-GM-CSF therapies in COVID-19 show divergent results, this may be explained by underlying biology and the fragility of the study findings. Further investigation of the pathophysiology of COVID-19 is required to better target therapies.
Description
Keywords
Journal Title
Eur Respir J
Conference Name
Journal ISSN
0903-1936
1399-3003
1399-3003
Volume Title
Publisher
European Respiratory Society (ERS)
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as All Rights Reserved
Sponsorship
MRC (MR/V006118/1)
KK is supported by grants from the Academy of Medical Sciences (SG023\1048) and NIHR Development and Skills Enhancement award (NIHR 302841). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. ACM is supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/V006118/1).